中山大学肿瘤中心教授、博士生导师

华南恶性肿瘤防治全国重点实验室课题组长

谭 静，中山大学肿瘤中心/华南恶性肿瘤防治全国重点实验室教授、博士生导师。2015年中山大学“百人计划”入选者, 2016年国家海外高层次人才青年项目获得者。2016年入选广东省“珠江人才计划”。谭静教授致力于运用高通量基因组测序平台研究华南高发恶性肿瘤的遗传与表观遗传变异，并结合肿瘤基因组和临床病理信息发现新的靶向治疗方法，鉴定肿瘤治疗耐药的分子机理。研究方向包括肿瘤遗传与表观遗传变异介导免疫逃逸机制、新型抗癌药物平台构建及筛选和肿瘤治疗耐药机制等。目前研究重点包括：①通过肿瘤基因组学和表观基因组学揭示肿瘤免疫逃逸机制。②鉴定肿瘤治疗耐药的分子机制以及靶向治疗标志物。③运用不同肿瘤模型研究靶向和化疗中的耐药机理及其临床转化研究。主持参与多项国家及地区基金项目。目前发表SCI论文50余篇，其中以第一作者或通讯作者（含共同）在Nature Genetics(2), Cancer Cell(2), Cancer Discovery(2), J Clin Invest(3),  Leukemia(2), Genes and Development, PNAS, Cancer Research(3), J Biol Chem等国际知名杂志上发表23篇论文。总他引次数超过4400次。H-index:27。

主持及参与项目

1. 中山大学“百人计划二期”急需人才，2015， 主持，   300万

2. 中组部“千人计划”青年项目引进人才，2016，主持 ， 200万

3. 国家自然科学基金面上项目，2017， 主持， 75万

4. 国家自然科学基金面上项目，2019，主持，55万

5. 国家自然科学基金国际(地区)合作与交流项目，“基于肾癌（透明细胞型肾细胞癌）表观遗传学系统图谱分析的精准治疗研究”，2017，参与，  165万

6. 广东省“珠江人才计划”引进创新创业团队项目，“自身免疫性关节炎和丙肝的免疫学负调控机制研究及其精准诊疗技术的研发”，2017，参与 ， 2000万

7. 广州市科技计划项目重点项目，“晚期鼻咽癌远处转移的精准医学研究”，2017，参与，300万

教育背景

2012年获得新加坡国立大学医学院肿瘤学专业  博士学位

2002年获得厦门大学生命科学学院生物化学与分子生物学专业  硕士学位

1999 年获得厦门大学生命科学学院生物技术专业   学士学位

科研工作经历

2015-至今 肿瘤医学协同创新中心 (Collaborative Innovation Center for Cancer Medicine)/PI

2015-至今 中山大学肿瘤中心/华南恶性肿瘤防治全国重点实验室担任教授/独立PI

2013-2015新加坡国立癌症研究中心肿瘤表观基因组研究室担任高级研究员

2012-2013新加坡基因组研究院肿瘤个体化治疗研究室担任博士后研究员

2004-2012年于新加坡基因组研究院肿瘤分子药理实验室担任高级实验员

2002年-2004 年于约翰斯 · 霍普金斯新加坡癌症肿瘤表观遗传学实验室担任实验员

申请专利

1. 于强, 谭静. 癌症治疗及肿瘤干细胞调控 (专利号: US8058258 B2).  2011.

2. 于强, 谭静. PDK1 激活 PLK1-Myc 信号通路在肿瘤干细胞及靶向 mTOR 治疗中耐药性作用机理发现(专利号: EP2521913 A1). 2012.

3. 谭静，黄慧强，陈竞红. 一种治疗复发/难治T细胞淋巴瘤的新型联合靶向药物 （ZL 2020 1 0108404.8）

学术任职

4. 中国抗癌协会病因学术委员会/肿瘤标志物委员会青年委员

5. 中国抗癌协会肿瘤标志物鼻咽癌委员

6. 美国AACR会员 （2014-至今）

代表性论文：

1. Deng P, Wang Z, Chen J, Liu S, Yao X, Liu S, Liu L, Yu Z, Huang Y, Xiong Z, Xiao R, Gao J, Liang W, Chen J, Liu H, Hong JH, Chan JY, Guan P, Chen J, Wang Y, Yin J, Li J, Zheng M, Zhang C, Zhou P, Kang T, Teh BT, Yu Q, Zuo Z, Jiang Q, Liu J, Xiong Y, Xia X, Tan J. RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancer. J Clin Invest. 2022 Oct 6:e159628. doi: 10.1172/JCI159628 (通讯作者，IF:19.456)

2. Sun Y, Gao Y, Chen J, Huang L, Deng P, Chen J, Chai KXY, Hong JH, Chan JY, He H, Wang Y, Cheah D, Lim JQ, Chia BKH, Huang D, Liu L, Liu S, Wang X, Teng Y, Pang D, Grigoropoulos NF, Teh BT, Yu Q, Lim ST, Li W, Ong CK, Huang H, Tan J. CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma. Cancer Lett. 2021 Sep2:S0304-3835(21)00438-9.doi:10.1016/j.canlet.2021.09.002. PMID: 34481935 (通讯作者，IF:8.6)

3. Zhaoliang Yu*, Peng Deng*, Yufeng Chen*, Shini Liu2, Jinghong Chen2, Zihuan Yang3, Jianfeng Chen2, Xinjuan Fan4, Peili Wang2, Zerong Cai1, Yali Wang2, Peishan Hu3, Dezheng Lin5, Rong Xiao6, Yifeng Zou1, Yan Huang4, Qiang Yu, Ping Lan, Jing Tan#, Xiaojian Wu#. Inhibition of the PLK1-coupled cell cycle machinery overcomes resistance to oxaliplatin in colorectal cancer. Advanced Science. 28 October 2021 doi.org/10.1002/advs.202100759 (#共同通讯，IF：16.8)

4. Liu S, Zou Q, Chen JP, Yao X, Guan P, Liang W, Deng P, Lai X, Yin J, Chen J, Chen R, Yu Z, Xiao R, Sun Y, Hong JH, Liu H, Lu H, Chen J, Bei JX, Koh J, Chan JY, Wang B, Kang T, Yu Q, Teh BT, Liu J, Xiong Y, Tan J. Targeting Enhancer Reprogramming to Mitigate MEK Inhibitor Resistance in preclinical models of Advanced Ovarian Cancer. J Clin Invest 2021 Oct 15;131(20):e145035. doi: 10.1172/JCI145035. (通讯作者，IF:19.456)

5. Liu L, Liu S, Deng P, Liang Y, Xiao R, Tang LQ, Chen J, Chen QY, Guan P, Yan SM, Huang X, Hong JH, Chen J, Sun Y, Teh BT, Yu Q, Mai HQ, Tan J. Targeting the IRAK1-S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma. Cancer Res. 2021 Mar 1;81(5):1413-1425. doi: 10.1158/0008-5472.CAN-20-2125. PMID: 33402387 （通讯作者，IF:13.5）

6. Xing M#, Ooi WF#, Tan J#, Qamra A, Lee PH, Li Z, Xu C, Padmanabhan N, Lim JQ, Guo YA, Yao X, Amit M, Ng LM, Sheng T, Wang J, Huang KK, Anene-Nzelu CG, Ho SWT, Ray M, Ma L, Fazzi G, Lim KJ, Wijaya GC, Zhang S, Nandi T, Yan T, Chang MM, Das K, Isa ZFA, Wu J, Poon PSY, Lam YN, Lin JS, Tay ST, Lee MH, Tan ALK, Ong X, White K, Rozen SG, Beer M, Foo RSY, Grabsch HI, Skanderup AJ, Li S, Teh BT, Tan P. Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer. J Clin Invest. 2020 May 4. pii: 126726. doi: 10.1172/JCI126726 （#共同一作，IF：19.468）

7. Nairismägi M, Gerritsen ME, Li ZM, Wijaya GC, Chia BKH, Laurensia Y, Lim JQ, Yeoh KW, Yao XS, Pang WL, Bisconte A, Hill RJ, Bradshaw JM, Huang D, Song TLL, Ng CCY, Rajasegaran V, Tang T, Tang QQ, Xia XJ, Kang TB, Teh BT, Lim ST, Ong CK, Tan J . Oncogenic Activation of JAK3-STAT Signaling Confers Clinical Sensitivity to PRN371, a Novel Selective and Potent JAK3 Inhibitor, in Natural Killer/T-cell Lymphoma Leukemia 2018 Feb 2. doi: 10.1038/s41375-017-0004 . （通讯作者，IF：11.702）

8. Yao X*, Tan J*, Lim KJ, Koh J, Ooi WF, Li Z, Huang D, Xing M, Chan YS, Qu JZ, Tay ST, Wijaya G, Lam YN, Hong JH, Lee-Lim AP, Guan P, Ng MSW, He CZ, Lin JS, Nandi T, Qamra A, Xu C, Myint SS, Davies JOJ, Goh JY, Loh G, Tan BC, Rozen SG, Yu Q, Tan IBH, Cheng CWS, Li S, Chang KTE, Tan PH, Silver DL, Lezhava A, Steger G, Hughes JR, Teh BT, Tan P., VHL deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinoma. Cancer Discov. 2017 Nov;7(11):1284-1305. doi: 10.1158/2159-8290.CD-17-0375. (*共同一作, IF=39.6)

9. M-L Nairismägi, J Tan*, J Q Lim, S Nagarajan, C C Y Ng, V Rajasegaran, D Huang, W K Lim, Y Laurensia, G C Wijaya, Z M Li, I Cutcutache, W L Pang, S Thangaraju, J Ha, L P Khoo, S T Chin, S Dey, G Poore, L H C Tan, H K M Koh, K Sabai, H-L Rao, K L Chuah, Y-H Ho, S-B Ng, S-S Chuang, F Zhang, Y-H Liu, T Pongpruttipan, Y H Ko, P-L Cheah, N Karim, W-J Chng, T Tang, M Tao, K Tay, M Farid, R Quek, S G Rozen, P Tan, B T Teh, S T Lim, S-Y Tan and C K Ong, JAK-STAT and G protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma. Leukemia. 2016 Feb 8. doi: 10.1038/leu.2016.13. (*共同一作, IF=11.702)

10. Tan J, Tan P, Teh BT. Defining the Molecular Alterations of Ampullary Carcinoma. Cancer Cell. 2016 Feb 8; 29 (2):135-136. doi: 10.1016/j.ccell.2016.01.011. (IF=39.407)

11. Tan J*, Ong CK*, Lim WK*, Ng CC, Thike AA, Ng LM, Rajasegaran V, Myint SS, Nagarajan S, Thangaraju S, Dey S, Nasir ND, Wijaya GC, Lim JQ, Huang D, Li Z, Wong BH, Chan JY, McPherson JR, Cutcutache I, Poore G, Tay ST, Tan WJ, Putti TC, Ahmad BS, Iau P, Chan CW, Tang AP, Yong WS, Madhukumar P, Ho GH, Tan VK, Wong CY, Hartman M, Ong KW, Tan BK, Rozen SG, Tan P, Tan PH, Teh BT. Genomic landscapes of breast fibroepithelial tumors. Nat Genet. 2015 Nov; 47(11):1341-5. doi: 10.1038/ng.3409 (IF=38.33).

12. Lim WK*, Ong CK*, Tan J*, Thike AA, Ng CC, Rajasegaran V, Myint SS, Nagarajan S, Nasir ND, McPherson JR, Cutcutache I, Poore G, Tay ST, Ooi WS, Tan VK, Hartman M, Ong KW, Tan BK, Rozen SG, Tan PH, Tan P, Teh BT. Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. Nat Genet. 2014 Aug; 46 (8):877-80. doi: 10.1038/ng.3037 (*共同一作, IF=38.33).

13. Tan J*, Yang XJ*, Jiang X, Zhou JB, Li ZM, Lee PL, Li BJ, Robson P, Yu Q.  Integrative epigenome analysis identifies a Polycomb-targeted differentiation program as a tumor suppressor event epigenetically inactivated in colorectal cancer. Cell Death Dis. 2014, 5: e1324 (IF=8.79)

14. Tan J, Li Z, Lee PL, Guan P, Aau MY, Lee ST, Feng M, Lim CZ, Lee EY, Wee ZN, Lim YC, Karuturi RK, Yu Q. PDK1 Signaling Towards PLK1-Myc Activation Confers Oncogenic Transformation and Tumor Initiating Cell Activation and Resistance to mTOR-targeted Therapy. Cancer Discov. 2013, 3(10):1156-71. (IF=39.6)

15. Tan J#, Yu Q "Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy." Chin J Cancer 2013 Jul 5 ; 32(7) : 376-9 Epub 2013 May 14 (#Corresponding author)

16. Tan J, Yu Q. PDK1-driven Myc signaling regulates cellular response to mTOR inhibitors. Cell Cycle. 2011, 10(7): 1019-1020. (IF=5.006)

17. Tan J, Lee PL, Li Z, Jiang X, Lim YC, Hooi SC, Yu Q. B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell. 2010, 18 (5): 459-71. (IF=39.407)

18. Jiang X*, Tan J*, Li J, Kivimäe S, Yang X, Zhuang L, Lee PL, Chan MT, Stanton LW, Liu ET, Cheyette BN, Yu Q. DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell. 2008, 13(6): 529-41. (co-first author, IF=39.407)

19. Li J*, Tan J*, Zhuang L, Banerjee B, Yang XJ, Chau JF, Lee PL, Hande MP, Li B, Yu Q.  Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress. Cancer Res. 2007, 67(23): 11317-26. (co-first author, IF=9.284)

20. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007, 21(9): 1050-63. (IF=12.639)

21. Tan J, Zhuang L, Jiang X, Yang KK, Karuturi KM, Yu Q.  Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity. J Biol Chem. 2006, 281 (15): 10508-15. (IF=4.60)

22. Zhao Y*, Tan J*, Zhuang L, Jiang X, Liu ET, Yu Q.  Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci U S A. 2005, 102 (44):16090-5. (co-first author, IF=9.806)

23. Tan J, Zhuang L, Leong HS, Iyer NG, Liu ET, Yu Q. Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Cancer Res. 2005, 65 (19): 9012-20. (IF=9.284)

更新时间：2023年1月9日